相关实验视频

Updated: Jul 14, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

转移性胰腺癌患者的第三线治疗选择:现实研究

Hong-Rui Lu^1,2, Peng-Fei Zhu^1,2, Ya-Ya Deng^2,3

¹Graduate School of Clinical Medicine, Bengbu Medical College, Bengbu, Anhui, China.

Frontiers in oncology

|October 9, 2023

概括

转移性胰腺癌 (mPC) 的第三线治疗可以延长存活时间. 然而,将向疗法或免疫疗法添加到化疗中并没有显著改善结果,但增加了不良事件.

科学领域:

在瘤学瘤学.
胃肠病学胃肠病学
临床研究临床研究

背景情况:

转移性胰腺癌 (mPC) 缺乏标准的第三线治疗方案.
现实世界的数据对于评估mPC治疗疗效至关重要.
本研究解决了在mPC中对第三线治疗进行比较分析的需要.

研究的目的:

为了比较mPC的各种第三线治疗方案的疗效和安全性.
评估第二线治疗后进展的患者的现实结果.
为了确定影响第三线mPC治疗生存的预后因素.

主要方法:

从2013年6月到2023年1月,对72名mPC患者的回顾性分析.
患者接受了单独的化疗,有针对性/免疫疗法的化疗,无化疗治疗或息治疗.
主要终点:平均整体存活率 (mOS),平均无进展存活率 (mPFS) 和疾病控制率 (DCR).

主要成果:

第三线治疗显示出不同的中位数无进展生存时间 (2.33-5.20个月) 和总生存时间 (3.33-6.90个月).
与单独的化疗相比,与向/免疫疗法结合的化疗有更多的不良事件 (100%) 和更高的3/4级超氨基转移酶 (31.3%).
在所有测量终点上,息治疗显著恶化了预后 (P < 0.001).

结论:

第三线抗瘤治疗可以延长mPC患者的存活时间.
向治疗或免疫疗法在添加到化疗时没有进一步改善生存益处.
良好的身体状况和家族癌症史是长时间mOS的独立预后因素.

关键词:

化疗化疗是一种化学疗法.免疫疗法免疫疗法胰腺癌是一种癌症.有针对性的治疗.这是第三线治疗.

更多相关视频

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

相关概念视频

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...